Minervax raises €47.4m in Series B funding round for GBS shotDenmark’s MinervaX has raised €47.4 million (around $56 million) in a Series B funding round to take its Share XMinervax raises €47.4m in Series B funding round for GBS shothttps://pharmaphorum.com/news/minervax-raises-e47-4m-in-series-b-funding-round-for-gbs-shot/
Sinovac raises $515m to boost production of potential COVID-19 vaccineChina’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its Share XSinovac raises $515m to boost production of potential COVID-19 vaccinehttps://pharmaphorum.com/news/sinovac-raises-515m-to-boost-production-of-potential-covid-19-vaccine/
Swiss start-up Noema raises $59m to develop neurology drugs offloaded by RocheSwiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in Share XSwiss start-up Noema raises $59m to develop neurology drugs offloaded by Rochehttps://pharmaphorum.com/news/swiss-start-up-noema-raises-59m-to-develop-neurology-drugs-offloaded-by-roche/
Sidekick Health raises $20m to fund digital therapeutics expansionGamified digital therapeutics firm Sidekick Health has raised $20 million in a Series A funding round, which it Share XSidekick Health raises $20m to fund digital therapeutics expansionhttps://pharmaphorum.com/news/sidekick-health-raises-20m-to-fund-digital-therapeutics-expansion/
SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
US snaps up first supplies of Regeneron’s COVID-19 antibodyHard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has Share XUS snaps up first supplies of Regeneron’s COVID-19 antibodyhttps://pharmaphorum.com/news/us-snaps-up-first-supplies-of-regenerons-covid-19-antibody/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
NodThera raises $55m in Series B round to trial inflammatory disease drugsThe Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory Share XNodThera raises $55m in Series B round to trial inflammatory disease drugshttps://pharmaphorum.com/news/nodthera-raises/
AI drug discovery firm Exscientia gets $60M cash injectionUK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round Share XAI drug discovery firm Exscientia gets $60M cash injectionhttps://pharmaphorum.com/news/ai-drug-discovery-firm-exscientia-gets-60m-cash-injection/
